Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved.
Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. Vtesse is working collaboratively with the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) and other leading academic centers to advance clinical study of VTS-270 for Niemann-Pick Type C1 Disease (NPC), and to identify and develop other novel drugs for other lysosomal storage diseases (LSDs).
Vtesse is lead by a highly experienced management team that has been involved in the development of more than 20 approved drugs and vaccines. Its consortium of investors, New Enterprise Associates (NEA), Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Real Estate Equities, Inc, has committed initial funding that is expected to bring this compound through the pivotal clinical trial. Vtesse is based in Gaithersburg, Maryland and is the first spin out of Cydan.
For more information, visit www.vtessepharma.com.
About Niemann-Pick C (NPC)
NPC is a progressive, irreversible, chronically debilitating – and ultimately lethal – genetic disease. It is caused by a defect in cholesterol transportation within the cell, which leads to excessive and lethal accumulation of cholesterol in the brain. Researchers at the NIH’s National Center for Advancing Translational Sciences (NCATS) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), in close collaboration with Vtesse, patients and patient advocacy groups, developed VTS-270 as part of a project focused on finding treatments for NPC. VTS-270 has been shown to significant slow disease progression in animal studies and preliminary indications of efficacy in the Phase I study clinical trial.